Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Revelando lo invisible en España: Cómo la tecnología UV-C está impactando al mercado europeo

Puntos críticos: La pandemia validó la tecnología UV-C para el mundo médico, y ahora se están encontrando usos en otras industrias. El mercado español tiene varios sectores donde los rayos ultravioletas tipo C puedes ser útiles. El ecosistema de tecnologías sanitarias será critico para la salud de gente en nuestros ambientes públicos. El último año…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Revelando lo invisible en España: Cómo la tecnología UV-C está impactando al mercado europeo

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite
  • La pandemia validó la tecnología UV-C para el mundo médico, y ahora se están encontrando usos en otras industrias.
  • El mercado español tiene varios sectores donde los rayos ultravioletas tipo C puedes ser útiles.
  • El ecosistema de tecnologías sanitarias será critico para la salud de gente en nuestros ambientes públicos.

El último año y medio de disrupciones sanitarias ha revelado la importancia de mejores prácticas para mantener la salud de la gente en lugares públicos y de alto tráfico. En el primer episodio hispanohablante de Making the Invisible, Visible, un podcast de Intellego Technologies exploramos los beneficios de UV-C en este contexto. Vamos a explorar los casos de uso para rayos ultravioletas tipo C en las tecnologías biomédicas, pero no solo explorando como funciona la tecnología; también daremos puntos de vista en como maximizar esta tecnología en un ecosistema de soluciones innovadoras.

Nuestras invitadas, Patricia Pregel y Verónica Vidal, explican cómo esta tecnología ha avanzada en años recientes, y porque en la región europea, específicamente en España, se puede encontrar usos en varias industrias. Darémos respuestas a preguntas importantes, como…

  1. ¿Cómo funciona como una solución biomédica, y cómo se compara a otros rayos ultravioletas?
  2. ¿Cómo funcionan entro del ecosistema de tecnologías de saneamiento? ¿Qué reemplazan y qué complementan?
  3. ¿En cuales sectores españoles hay la mayoría de la oportunidades para usar el ecosistema de productos UV-C, y por qué?

Más información sobre nuestras invitadas:

  • Patricia Pregel es la directora de ventas de Intellego Technologies para el sur de Europa, LATAM y África.
  • Verónica Vidal está a cargo de Directora de Biodosimetría e Innovación para Fotoglass, una compañía creando aplicaciones ópticas para el sector industrial y biomédico, validando a la eficacia de tecnología crítica a estos sectores.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512